肿瘤浸润淋巴细胞在胰腺癌中研究进展  

Progress in research of tumor infiltrating lymphocytes in pancreatic cancer

作　　者：祝文君 胡湛斐 袁周[2] Wen-Jun Zhu;Zhan-Fei Hu;Zhou Yuan(CAR-T(Shanghai)Cell Biotechnology Co.,Ltd,Shanghai 200433,China;The Sixth People’s Hospital Affiliated to Shanghai Jiaotong University,Shanghai 200233,China)

机构地区：[1]卡替(上海)细胞生物技术有限公司,上海市200433 [2]上海交通大学附属第六人民医院,上海市200233

出　　处：《世界华人消化杂志》2021年第21期1207-1214,共8页World Chinese Journal of Digestology

摘　　要：胰腺癌五年生存率低于5%,现有的治疗手段治疗效果有限,针对胰腺癌的治疗仍面临巨大挑战.肿瘤浸润淋巴细胞(tumor infiltrating lymphocyte,TIL)是肿瘤微环境的重要组成部分,起到主导肿瘤微环境局部免疫反应的作用,是许多癌症的有利预后因素.TIL能够特异性地识别肿瘤细胞,通过细胞免疫对这些肿瘤细胞进行杀伤.TIL疗法已经被证明在黑色素瘤、宫颈癌、乳腺癌等实体瘤中具有良好的治疗效果,但是应用TIL治疗胰腺癌仍然存在一些难点,包括新生抗原的筛选、TIL快速扩增、导向到肿瘤部位及细胞衰竭.本文将就近年来人们对TIL在胰腺癌中的研究进行概述,挖掘TIL在胰腺癌治疗中的潜在应用价值.The 5-year survival rate of pancreatic cancer is less than 5%,and the only available treatments,surgery,chemotherapy,and chemoradiation,have shown limited effectiveness.Therefore,alternative treatment strategies are urgently needed.In recent years,tumor infiltrating lymphocyte(TIL)therapy has shown promising successes in the treatment of some types of solid tumors because of its diverse TCR clonality,superior tumor-homing ability,and low off-target toxicity.The significant association between a high TIL density in pancreatic cancer tissue and a good clinical outcome and success of pancreatic cancer-specific TIL expansion ex vivo potentiates the rationality of the TIL therapy in pancreatic cancer.However,there are still many challenges ahead,such as neoantigen screening,rapid cell expansion,and low cytotoxicity.This article reviews the recent advances and limitations of TIL therapy in pancreatic cancer and discusses its future directions.

关 键 词：胰腺癌 肿瘤浸润淋巴细胞 预后评价 细胞治疗 肿瘤微环境 免疫治疗 

分 类 号：R735.9[医药卫生—肿瘤]